Agilent Technologies, Inc.
- Home
- Companies
- Agilent Technologies, Inc.
- Products
- Model ClearSeq AML - NGS Disease ...
Model ClearSeq AML -NGS Disease Research Panels
The ClearSeq AML panel targets 20 genes identified by leading researchers to be frequently mutated in acute myeloid leukemia (AML). It is designed for full coverage of target regions with multiple amplicons covering each target for greater confidence in somatic variant calling. Combined with intuitive data analysis workflows in Agilent’s SureCall software, you can now profile your myeloid samples.
Most popular related searches
Expert - Identified Content
- Designed in collaboration with Dr. Robert Ohgami and Dr. Daniel Arber at Stanford University
- Targets 20 key genes frequently mutated in AML
Premium Performance You Can Trust
- Provides 99.9% design coverage of targeted exons
- Library-prep free target enrichment in less than a day
Comprehensive Workflow Solution
- Get from raw data to mutation reports in 3 simple steps using SureCall Analysis Software
- Obtain all reagents for sample preparation, QC, and automation tools from one trusted partner